Search

Displaying results 3511 - 3520 of 4588 in total
  1. Drug

    RPI-MN

    go.drugbank.com/drugs/DB17957
    Experimental

    [A260132] Being developed by Nutra Pharma under the trade name PEPTERON, it is being investigated for the treatment of neurological and immune disorders.[L47107]

  2. Drug

    Nurulimab

    go.drugbank.com/drugs/DB18946
    Investigational

    Nurulimab is under investigation in clinical trial NCT05732805 (A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-pd-1 Compared to Anti-pd-1 Monotherapy as First-line Treatment in

  3. Drug

    Q-Derp1

    go.drugbank.com/drugs/DB05857
    Experimental

    Q-Derp1 is developed by Cytos Biotechnology as an immunodrug. It is an antigen for the prevention of various major chronic diseases. Derp1 is the dominant allergic protein found in dust mite feces.

  4. Drug

    Octopamine

    go.drugbank.com/drugs/DB13251
    Experimental

    It has been used as a nootropic, and therefore it and all of its enantiomer are prohibited by the World Anti-doping Agency (WADA) as of 2014.

  5. Drug

    Stanolone

    go.drugbank.com/drugs/DB02901
    IllicitInvestigational

    Dihydrotestosterone (DHT) is generated by a 5-alpha reduction of testosterone. Unlike testosterone, DHT cannot be aromatized to estradiol therefore DHT is considered a pure androgenic steroid.

  6. Drug

    Flutamide

    go.drugbank.com/drugs/DB00499
    ApprovedInvestigational

    An antiandrogen with about the same potency as cyproterone in rodent and canine species.

  7. Drug

    Chromous sulfate

    go.drugbank.com/drugs/DB14530
    Approved

  8. Drug

    XL765

    go.drugbank.com/drugs/DB05241
    Investigational

    It is being developed by Exelixis, Inc.

  9. Drug

    RI 624

    go.drugbank.com/drugs/DB05892
    Experimental

    RI 624 is being developed by Rinat and is currently in Phase I clinical trials.

  10. Drug

    Velsecorat

    go.drugbank.com/drugs/DB16347
    Investigational

    Velsecorat is under investigation in clinical trial NCT02479412 (A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients